---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-011766"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T02:47:32.570534+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BridgeBio prices $250M public offering at $29.00/share; funds acoramidis launch and pipeline

## Summary
- 8,620,690 shares priced at $29.00; underwriters have 30-day option for 1,293,103 additional shares.
- Net proceeds estimated at ~$250M; expected to fund operations into H2 2026.
- Proceeds to support commercial launch of acoramidis, if approved, and clinical/preclinical development.
- Offering expected to close March 8, 2024; 60-day lock-up for directors and officers.
- J.P. Morgan, Cantor Fitzgerald, Mizuho act as joint book-running managers.

## SEC filing metadata
- accession: 0001140361-24-011766
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000114036124011766/0001140361-24-011766-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000114036124011766/ny20019103x3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-011766
- JSON: https://secwatch.observer/filing/0001140361-24-011766.json
- Plain text: https://secwatch.observer/filing/0001140361-24-011766.txt

## Key facts
- Material Agreements
  BridgeBio Pharma, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of the several underwriters valued at approximately $250.0 million (effective 2024-03-05).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of the several underwriters
  - Value: approximately $250.0 million
  - Effective: 2024-03-05
  source text: On March 5, 2024, BridgeBio Pharma, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of the several underwriters listed on Schedule I thereto (collectively, the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 8,620,690 shares of the Company's common stock, $0.001 par value per share (the “Common Stock”), at a price to the public of $29.00 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000114036124011766/0001140361-24-011766-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.